Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Allografting

Disease status is a more reliable predictive factor than histology in lymphoma patients after reduced-intensity conditioning regimen and allo-SCT

Bone Marrow Transplantation volume 48, pages 794–798 (2013)Cite this article

Subjects

A Corrigendum to this article was published on 07 February 2018

Abstract

We analyzed 113 patients with lymphoma who underwent allogeneic transplantation with reduced-intensity conditioning (allo-RIC) regimens at a single institution, from February 2001 through November 2009, searching for factors predictive of the outcome. At the time of transplantation, 60% of patients were in CR, 29% in PR and 11% had progressive or stable disease. At a median follow-up of 34 months (confidence interval (CI) 17–45), the 3-year OS and PFS were 59% (CI 48–68%) and 51% (CI 41–61%), respectively. The 100-day and 2-year nonrelapse mortalities (NRM) were 6% and 28% (CI 20–35%), respectively. Grade II–IV acute GVHD (aGVHD) incidence was 38%, and the global incidence of chronic GVHD was 33%. In univariate analysis, OS was influenced by disease status before allo-RIC; aGVHD negatively affected on survival. Similarly, PFS was influenced only by disease status. Histological subtype did not affect OS or PFS. We conclude that disease status at the time of transplantation significantly influences survival in patients receiving allo-RIC for lymphoma, whereas histological subtype does not. This reinforces the need to administer more effective debulking treatments to lymphoma patients, for optimal benefit of allogeneic immune recognition of minimal residual disease, independently from lymphoma histology.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Robinson SP, Goldstone AH, Mackinnon S, Carella A, Russell N, de Elvira CR et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the lymphoma working party of the European Group for blood and bone marrow transplantation. Blood 2002; 100: 4310–4316.

    Article  CAS  Google Scholar 

  2. Rezvani AR, Norasetthada L, Gooley T, Sorror M, Bouvier ME, Sahebi F et al. Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience. Br J Haematol 2008; 143: 395–403.

    Article  Google Scholar 

  3. Sureda A, Canals C, Arranz R, Caballero D, Ribera JM, Brune M et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin’s lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the lymphoma working party of the European Group for blood and marrow transplantation. Haematologica 2012; 97: 310–317.

    Article  Google Scholar 

  4. Le Gouill S, Milpied N, Buzyn A, De Latour RP, Vernant JP, Mohty M et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire. J Clin Oncol 2008; 26: 2264–2271.

    Article  Google Scholar 

  5. Khouri IF, Saliba RM, Giralt SA, Lee MS, Okoroji GJ, Hagemeister FB et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 2001; 98: 3595–3599.

    Article  CAS  Google Scholar 

  6. Tam CS, Bassett R, Ledesma C, Korbling M, Alousi A, Hosing C et al. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 2009; 113: 4144–4152.

    Article  CAS  Google Scholar 

  7. Chakraverty R, Mackinnon S . Allogeneic transplantation for lymphoma. Clin Oncol 2011; 29: 1855–1863.

    Article  Google Scholar 

  8. Kyriakou C, Canals C, Finke J, Kobbe G, Harousseau JL, Kolb HJ et al. Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 2009; 27: 3951–3958.

    Article  Google Scholar 

  9. Milpied N, Fielding AK, Pearce RM, Ernst P, Goldstone AH . Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin’s disease. European Group for Blood and Bone Marrow Transplantation. J Clin Oncol 1996; 14: 1291–1296.

    Article  CAS  Google Scholar 

  10. Akpek G, Ambinder RF, Piantadosi S, Abrams RA, Brodsky RA, Vogelsang GB et al. Long-term results of blood and marrow transplantation for Hodgkin’s lymphoma. J Clin Oncol 2001; 19: 4314–4321.

    Article  CAS  Google Scholar 

  11. Sorror M, Storer B, Sandmaier BM, Maloney DG, Chauncey TR, Langston A et al. Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer 2008; 112: 1992–2001.

    Article  Google Scholar 

  12. Armand P, Kim HT, Ho VT, Cutler CS, Koreth J, Antin JH et al. Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant 2008; 14: 418–425.

    Article  CAS  Google Scholar 

  13. Corradini P, Dodero A, Farina L, Fanin R, Patriarca F, Miceli R et al. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia 2007; 21: 2316–2323.

    Article  CAS  Google Scholar 

  14. Kahl C, Storer BE, Sandmaier BM, Mielcarek M, Maris MB, Blume KG et al. Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2007; 110: 2744–2748.

    Article  CAS  Google Scholar 

  15. Blaise D, Tabrizi R, Boher JM, Le Corroller-Soriano AG, Bay JO, Fegueux N et al. Randomized study of 2 reduced-intensity conditioning strategies for human leukocyte antigen-matched, related allogeneic peripheral blood stem cell transplantation: prospective clinical and socioeconomic evaluation. Cancer, (e-pub ahead of print 14 August 2012; doi:10.1002/cncr.27786).

    Article  Google Scholar 

  16. Mohty M, Bay JO, Faucher C, Choufi B, Bilger K, Tournilhac O et al. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood 2003; 102: 470–476.

    Article  CAS  Google Scholar 

  17. Morris E, Thomson K, Craddock C, Mahendra P, Milligan D, Cook G et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 2004; 104: 3865–3871.

    Article  CAS  Google Scholar 

  18. Robinson SP, Sureda A, Canals C, Russell N, Caballero D, Bacigalupo A et al. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin’s lymphoma: identification of prognostic factors predicting outcome. Haematologica 2009; 94: 230–238.

    Article  Google Scholar 

  19. Vigouroux S, Michallet M, Porcher R, Attal M, Ades L, Bernard M et al. Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). Haematologica 2007; 92: 627–634.

    Article  Google Scholar 

  20. Hari P, Carreras J, Zhang MJ, Gale RP, Bolwell BJ, Bredeson CN et al. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant 2008; 14: 236–245.

    Article  Google Scholar 

  21. Armand P, Gibson CJ, Cutler C, Ho VT, Koreth J, Alyea EP et al. A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood 2012; 120: 905–913.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hematology Department, Transplantation Program, Institut Paoli Calmettes, Marseille, France

    L Castagna, S Furst, J El Cheikh, C Faucher, R Crocchiolo, A Granata, C Chabannon, C Lemarié, B Calmels & D Blaise

  2. Hematology Department, Lymphoma Program, Institut Paoli Calmettes, Marseille, France

    R Boubdallah & D Coso

  3. Biostatistic Department, Institut Paoli Calmettes, Marseille, France

    J M Boher

  4. Hematology Department, CHU Nantes, Nantes, France

    M Mohty

Authors
  1. L Castagna
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R Boubdallah
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Furst
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D Coso
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J El Cheikh
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C Faucher
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R Crocchiolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A Granata
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. C Chabannon
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. C Lemarié
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. B Calmels
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. J M Boher
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. M Mohty
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. D Blaise
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L Castagna.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Castagna, L., Boubdallah, R., Furst, S. et al. Disease status is a more reliable predictive factor than histology in lymphoma patients after reduced-intensity conditioning regimen and allo-SCT. Bone Marrow Transplant 48, 794–798 (2013). https://doi.org/10.1038/bmt.2012.225

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2012.225

Keywords

Search

Advanced search

Quick links